

G.H., O.P., R.G. and G.R. are employed by ARS, a public health agency that conducts or participates in pharmacoepidemiology studies compliant with the ENCePP Code of Conduct. The budget of ARS is partially sustained by such studies.

P.G received personal fees from Allergan, Eli Lilly, Novartis, Amgen, TEVA, Menarini, Elettrocore, Pfizer, IBSA; Grants from Amgen, TEVA, Eli Lilly, Allergan, Chiesi; Advisory Board for Endosome Therapeutics, Sanofi; Founding scientist of FloNext srl, Spinoff of the University of Florence. F.D.C received personal fees from TEVA, Eli Lilly, Novartis.

Other authors have no conflicting interests.